Anti-LOX 1 Antibody [LOX19-22] (A280937)

Anti-LOX 1 Antibody [LOX19-22]

Mouse monoclonal [LOX19-22] antibody to LOX 1.

This antibody recognises the lectin-like oxidised low-density lipoprotein (LDL) receptor (LOX-1), a 31kDa protein of the C-type lectin superfamily. This receptor mediates the recognition, internalisation and degradation of oxidised LDL. It is a Type II membrane protein with a typical C-type lectin structure at the extracellular C-terminus which recognises the ligand. LOX-1 activation by oxidised LDL causes endothelial changes such as decreased nitric oxide release and an increased expression of adhesion molecules. LOX-1 also binds activated platelets and apoptotic cells. The expression of LOX-1 is induced by proatherogenic conditions such as hyperlipidemia, hypertension and diabetes and as such appears to contribute to the pathogenesis of vascular disorders, particularly atherosclerosis. It can be cleaved by an unknown protease at the extracellular juxtamembrane region to release the soluble form (aa58-273) of LOX-1, recognized by Mouse anti Human LOX-1 (Soluble) antibody, clone LOX19-22.

WB, ELISA

Human

Recombinant soluble LOX-1 expressed in E.coli.

Mouse

Monoclonal

LOX19-22

IgG1

Protein A affinity chromatography of tissue culture supernatant.

Liquid

Supplied in Phosphate Buffered Saline with <0.1% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Mouse anti Human LOX-1 (Soluble) antibody, clone LOX19-22 recognizes the lectin-like oxidised low-density lipoprotein (LDL) receptor (LOX-1), a 31kDa protein of the C-type lectin superfamily. This receptor mediates the recognition, internalisation and degradation of oxidised LDL. It is a Type II membrane protein with a typical C-type lectin structure at the extracellular C-terminus which recognizes the ligand. LOX-1 activation by oxidised LDL causes endothelial changes such as decreased nitric oxide release and an increased expression of adhesion molecules. LOX-1 also binds activated platelets and apoptotic cells. The expression of LOX-1 is induced by proatherogenic conditions such as hyperlipidemia, hypertension and diabetes and as such appears to contribute to the pathogenesis of vascular disorders, particularly atherosclerosis. It can be cleaved by an unknown protease at the extracellular juxtamembrane region to release the soluble form (aa58-273) of LOX-1, recognized by Mouse anti Human LOX-1 (Soluble) antibody, clone LOX19-22.

C-type lectin domain family 8 member A, CLEC8A, hLOX-1, Lectin-like oxidized LDL receptor 1, Lectin-like oxLDL receptor 1, Lectin-type oxidized LDL receptor 1, LOX-1, LOX1, Ox-LDL receptor 1, Oxidized low-density lipoprotein receptor 1